Semax (5 mg Vial)

Intranasal (IN) Research Summary

Semax has been studied extensively via the intranasal route in human clinical and preclinical settings. The following bullets summarize reported findings from the literature. All stated amounts are reported in studies unless otherwise noted.

• Primary studied route: Intranasal delivery (nasal drops or spray) is the predominant administration route in published human research for Semax; oral bioavailability is poor due to rapid enzymatic degradation^[1][14]. (Reported in studies.)
• Approved formulation (Russia): Semax is registered as a 0.1% intranasal solution (equivalent to 1,000 mcg/mL or 1.0 mg/mL) dispensed via dropper bottle; each standard drop is reported to deliver approximately 50 mcg of peptide^[2]. (Reported in studies.)
• Higher‑concentration formulation: A 1% Semax intranasal solution (10,000 mcg/mL or 10.0 mg/mL) has been used in acute neurological settings (e.g., ischemic stroke) to deliver larger amounts per actuation without excessive volume^[3][2]. (Reported in studies.)
• Delivery device: Published clinical protocols describe a dropper bottle with a cap‑pipette; some formulations reference a metered nasal spray. Specific per‑actuation delivered volume for spray devices was not consistently reported across studies^[2][11]. (Reported in studies; device output not standardized across sources.)
• Cognitive/neuroprotective studies (human): In adult cerebrovascular patients, total daily intranasal amounts of 200–6,000 mcg (divided into 3–4 administrations) were reported over courses of 5–14 days, with lower ranges (200–900 mcg/day) used for milder cognitive indications over shorter durations^[2][3]. (Reported in studies.)
• Pediatric study (human): In children ages 7–18 with minimal brain dysfunction, daily intranasal amounts of 200–400 mcg (approximately 5–6 mcg/kg) divided into two administrations were reported over a 30‑day course^[2]. (Reported in studies.)
• Optic neuropathy study (human): In 36 patients with glaucomatous optic neuropathy, daily intranasal Semax was administered for approximately one month; no significant adverse effects were reported^[6]. (Reported in studies.)
• Pharmacokinetic notes: Intranasal Semax is reported to have a short duration of action, necessitating multiple daily administrations in clinical protocols. Preclinical comparison of intranasal versus injection routes showed differences in onset and duration profiles, with injection providing more sustained systemic levels^[4][5]. (Reported in studies.)
• Variability and limitations: Intranasal bioavailability is subject to individual anatomical variation, mucosal condition, and device‑specific delivery volumes. Most published human data originate from Russian clinical registries and journals; large‑scale Western randomized controlled trials are lacking^[14][12]. (Inference based on available evidence.)

Nasal Spray Device Output & Conversion Math

Important: Nasal spray pumps vary significantly in delivered volume per actuation depending on manufacturer, pump mechanism, and priming. The mcg delivered per spray depends entirely on the specific device used. Always use manufacturer specifications or direct gravimetric measurement to determine delivered volume per actuation.

Parameterized Framework

Given two known inputs, the amount per actuation can be calculated:

• Input 1: concentration_mcg_per_mL (or convert from mg/mL × 1,000)
• Input 2: pump_output_mL_per_actuation (from device specs or measurement)
• Output: amount_mcg_per_actuation = concentration_mcg_per_mL × pump_output_mL_per_actuation

Optional volume mapping (U‑100 convention): If a “units” convention is used as a volume measure, 100 units = 1.0 mL. Therefore: pump_output_mL_per_actuation = units_per_actuation ÷ 100, and amount_mcg_per_actuation = concentration_mcg_per_mL × (units_per_actuation ÷ 100).

Nasal Actuation Calculation Table (Placeholders)

Note: Concentrations above correspond to 5 mg reconstituted in 3.0 mL (1,667 mcg/mL) or 2.0 mL (2,500 mcg/mL). Pump output values are common placeholder ranges — verify with your specific device.

Worked Examples (Placeholders Only)

Example 1 (mL‑based): If concentration = 1,667 mcg/mL and pump output = 0.10 mL/actuation, then amount per actuation = 1,667 × 0.10 = 166.7 mcg.

Example 2 (units‑based): If concentration = 1,667 mcg/mL and pump output = 13 units/actuation, then pump output in mL = 13 ÷ 100 = 0.13 mL, and amount per actuation = 1,667 × 0.13 = 216.7 mcg.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (Semax, 5 mg each):
  • 8 weeks ≈ 5 vials
  • 12 weeks ≈ 8 vials
  • 16 weeks ≈ 10 vials
• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
  • 12 weeks (8 vials): 24 mL → 3 × 10 mL bottles
  • 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Semax effects are dose‑dependent; start conservatively and increase only as needed^[2].

How This Works

Semax is a stabilized synthetic analog of the adrenocorticotropic hormone fragment ACTH(4–10), designed to resist enzymatic degradation and enhance central nervous system bioavailability^[5][11]. Preclinical and clinical research indicates that Semax modulates BDNF expression, supports neuronal survival, and influences monoaminergic neurotransmission^[1]. In human studies, Semax has demonstrated cognitive‑enhancing effects in patients with cerebrovascular conditions and minimal brain dysfunction, with courses typically lasting 10–30 days at daily intranasal doses of 200–6,000 mcg depending on severity^[2][3]. When administered subcutaneously, systemic absorption is more sustained compared to the intranasal route, potentially allowing once‑daily dosing^[4].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

• Supports cognitive function, attention, and memory in subjects with cerebrovascular or mild cognitive impairment^[2][3].
• Neuroprotective properties observed in ischemic stroke models, with clinical trials reporting favorable neurological recovery outcomes^[3].
• Studied in optic neuropathy with reported stabilization of visual function over month‑long courses^[6].
• Generally well tolerated in clinical use; no significant adverse effects reported at standard doses in published studies^[2][6].
• Occasional mild injection‑site reactions (redness, minor irritation) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Prioritize quality sleep (7–9 hours) to support neurocognitive recovery and neuroplasticity.
• Engage in regular aerobic exercise, which independently supports BDNF expression and cognitive function.
• Maintain a nutrient‑dense diet rich in omega‑3 fatty acids, antioxidants, and B vitamins to support neuronal health.
• Manage chronic stress through mindfulness or relaxation techniques, as elevated cortisol can impair cognitive outcomes.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources^[10].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[7][8].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[7].
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[9].